Quantcast

Latest United Therapeutics Corporation Stories

2014-08-29 12:25:03

SILVER SPRING, Md., Aug. 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. District Court for the District of New Jersey has ruled in its favor in the company's case against Sandoz, Inc. regarding United Therapeutics' Remodulin(®) product. In his opinion, Judge Peter Sheridan ruled that U.S. Patent No. 6,765,117 is both valid and enforceable against Sandoz, Inc., and enjoined Sandoz from marketing its generic product until the...

2014-07-29 08:31:29

-- Total Revenues of $322.8 million SILVER SPRING, Md., July 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2014. "Our continued growth shows that our medicines are reaching increasing numbers of patients suffering from pulmonary arterial hypertension (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The commercial launch this quarter of our...

2014-07-22 08:30:30

SILVER SPRING, Md., July 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2014 financial results before market open on Tuesday, July 29, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, July 29, 2014, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will...

2014-06-27 08:24:42

SILVER SPRING, Md., June 27, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the company's common stock. This program will become effective on August 1, 2014, and will remain open for up to one year. Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by United Therapeutics' management and in...

2014-05-06 08:32:48

Lung Biotechnology Also Makes $50M Equity Investment in SGI LA JOLLA, Calif. and SILVER SPRING, Md., May 6, 2014 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have entered into a multi-year research and development agreement to develop humanized pig organs...

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...

2014-04-29 08:33:58

SILVER SPRING, Md., April 29, 2014 /PRNewswire/ -- -- Revenues of $289.4 million -- Net income of $137.5 million -- Earnings per Share of $2.73 per Basic Share or $2.43 per Diluted Share -- Non-GAAP Earnings of $1.77 per Basic Share or $1.57 per Diluted Share United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2014. "I am happy to report that our revenues and profits have risen nicely in line with...

2014-04-22 08:32:17

SILVER SPRING, Md., April 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2014 financial results before market open on Tuesday, April 29, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, April 29, 2014, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will...

2014-03-26 08:28:21

SILVER SPRING, Md., March 26, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin(®) (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost(TM) by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with...

2014-02-25 08:30:36

SILVER SPRING, Md., Feb. 25, 2014 /PRNewswire/ -- -- Total Annual Revenues of $1.1 billion -- Annual Earnings per Share of $3.49 per Basic Share or $3.28 per Diluted Share -- Annual Non-GAAP Earnings of $10.88 per Basic Share or $10.23 per Diluted Share United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2013. "United Therapeutics continued to deliver strong results in 2013,...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related